Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 780

recruiting
3 968
countries
28
conditions
2 103

10 282 trials match your criteria

Metastases to central nervous system+2

Not recruiting

Study on JDQ443 for Patients with KRAS G12C+ Non-Small Cell Lung Cancer and Brain Metastases

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:1-{6-[(4M)-4-(5-Chloro-6-Methyl-1H -Indazol-4-Yl)-5-Methyl-3-(1-Methyl-1H -Indazol-5-Yl)-1H -Pyrazol-1-Yl]-2-Azaspiro[3.3]Heptan-2-Yl}Prop-2-En-1-One

Cholangiocarcinoma

Not recruiting

Study of Durvalumab and Tremelimumab with Y-90 SIRT Therapy for Patients with Advanced Intrahepatic Biliary Tract Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab

Triple negative breast cancer

Not recruiting

Study on Triple Negative Breast Cancer Treatment with Chemotherapy, Fasting-Mimicking Diet, and Metformin for Preoperative Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Metformin Hydrochloride

Portal hypertension

Not recruiting

Study on the Effects of BI 685509 for Patients with Liver Cirrhosis and Portal Hypertension After First Decompensation Event

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bi 685509

Non-small cell lung cancer

Not recruiting

Study Comparing Zimberelimab and Domvanalimab with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Domvanalimab

Chronic obstructive pulmonary disease

Not recruiting

Study Comparing Trelegy with LABA-LAMA Drug Combination for Improving COPD Control in High-Risk Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aclidinium Bromide

Oesophageal squamous cell carcinoma+2

Not recruiting

Study on Budesonide Tablets for Preventing Esophageal Narrowing in Adults After Cancer Tissue Removal

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide

Pulmonary arterial hypertension

Not recruiting

Study on Seralutinib for Treating Pulmonary Arterial Hypertension in Patients

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Seralutinib

Diffuse large B-cell lymphoma+2

Not recruiting

Study of Glofitamab and Obinutuzumab for Patients with Relapsed or Refractory Lymphomas After CAR T-cell Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab

Non-small cell lung cancer

Not recruiting

Study of Immunotherapy Combinations Including Zimberelimab for Patients With Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Biliary neoplasm

Not recruiting

Study of pembrolizumab with gemcitabine and cisplatin as first treatment for patients with advanced or inoperable bile duct cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin

Chronic spontaneous urticaria

Not recruiting

Study on Extending Omalizumab Treatment Intervals for Adults with Well-Controlled Chronic Spontaneous Urticaria

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Omalizumab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.